MDT-AP-3207
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 20.52
- os_event
- false
- age_years
- 14.03
- sex
- M
- new_clusters
- C6
- umap1_2d
- 2.771177922
- umap2_2d
- 6.496016721
- umap1_3d
- 2.308724803
- umap2_3d
- -0.718497333
- umap3_3d
- -4.543571053
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.470
- HEME_METABOLISM+0.180
- PI3K_AKT_MTOR_SIGNALING+0.110
- ADIPOGENESIS+0.090
- OXIDATIVE_PHOSPHORYLATION+0.070
- UNFOLDED_PROTEIN_RESPONSE+0.070
- PEROXISOME+0.050
- SPERMATOGENESIS+0.030
- DNA_REPAIR+0.000
- FATTY_ACID_METABOLISM-0.020
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.560
- ANGIOGENESIS-0.480
- INFLAMMATORY_RESPONSE-0.470
- ALLOGRAFT_REJECTION-0.460
- INTERFERON_GAMMA_RESPONSE-0.430
- INTERFERON_ALPHA_RESPONSE-0.400
- TNFA_SIGNALING_VIA_NFKB-0.370
- APICAL_SURFACE-0.360
- IL2_STAT5_SIGNALING-0.360
- MYOGENESIS-0.360
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-2991 | Med | Medulloblastoma | 0.952 |
| 2 | MDT-AP-0395 | Med | Medulloblastoma | 0.945 |
| 3 | BS_J8G4SH4Z | Med | Medulloblastoma | 0.912 |
| 4 | TCGA-A8-A08C-01A-11R-A00Z-07 | — | B | 0.905 |
| 5 | MDT-AP-1341 | Med | Medulloblastoma | 0.902 |
| 6 | MDT-AP-0119 | Med | Medulloblastoma | 0.902 |
| 7 | SRR657325 | GTEX | — | 0.901 |
| 8 | MDT-AP-1354 | Med | Medulloblastoma | 0.899 |
| 9 | SRR819999 | GTEX | — | 0.899 |
| 10 | SRR664819 | GTEX | — | 0.896 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 8 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.470 | Remibrutinib | — uncovered |
| HEME_METABOLISM | 0.180 | Temsirolimus | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.110 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.090 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.070 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.070 | Idelalisib | — uncovered |
| PEROXISOME | 0.050 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.030 | Inavolisib | — uncovered |